16.44
+0.3(+1.86%)
Currency In USD
| Previous Close | 16.14 |
| Open | 16.14 |
| Day High | 16.54 |
| Day Low | 15.32 |
| 52-Week High | 41.31 |
| 52-Week Low | 12.21 |
| Volume | 746,718 |
| Average Volume | 949,360 |
| Market Cap | 504.16M |
| PE | -3.21 |
| EPS | -5.12 |
| Moving Average 50 Days | 16.54 |
| Moving Average 200 Days | 25.35 |
| Change | 0.3 |
If you invested $1000 in AnaptysBio, Inc. (ANAB) since IPO date, it would be worth $967.06 as of March 20, 2025 at a share price of $16.44. Whereas If you bought $1000 worth of AnaptysBio, Inc. (ANAB) shares 5 years ago, it would be worth $1,240.75 as of March 20, 2025 at a share price of $16.44.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Anaptys Announces Participation in March Investor Conferences
GlobeNewswire Inc.
Feb 27, 2025 9:15 PM GMT
SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer o
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
GlobeNewswire Inc.
Feb 11, 2025 10:30 PM GMT
SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review top-line data from
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference
GlobeNewswire Inc.
Feb 03, 2025 9:15 PM GMT
SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer o